Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
ANAB filing under Rule 144 reports a proposed sale of 15,000 common shares via a stock option exercise on 05/29/2026. The filing lists multiple recent dispositions by Dennis Mulroy with trade dates and gross proceeds, including sales on 05/28/2026 (10,264 shares, $594,671.20) and earlier May sales.
ANAB — Form 144 filing reports planned and recent sales of common stock by Dennis Mulroy. The notice lists a stock option exercise on 05/28/2026 covering 10,264 shares to be sold for cash. The filing also itemizes recent sales totaling 75,467 shares across dates in May 2026 with reported gross proceeds per trade.
Dennis Mulroy reported multiple proposed sales of Common Stock on a Form 144, including notices to sell 10,000 shares tied to a stock option exercise dated 05/27/2026. The excerpt lists several recent dispositions dated 05/15/2026–05/26/2026 with gross proceeds shown for each sale.
An affiliate filing to sell shares via Form 144. The filing lists a stock option exercise for 10,000 shares dated 05/26/2026 to be sold for cash. The excerpt also reports multiple recent dispositions by Dennis Mulroy on 05/22/2026, 05/21/2026, 05/19/2026, and 05/15/2026 with specific share counts and gross proceeds.
ANAB affiliate files a proposed sale of 10,000 shares. The filing notifies a stock option exercise sale of 10,000 shares on 05/22/2026 for cash. The filing also lists recent sales by the reporting person: 15,467 shares on 05/21/2026 for $928,071.04, 10,000 shares on 05/19/2026 for $599,000.00, and 10,000 shares on 05/15/2026 for $632,543.00.
AnaptysBio, Inc. is changing its fiscal year-end from December 31 to June 30, as approved by its board of directors on May 18, 2026. The next fiscal year will begin on July 1, 2026.
The company will file a transition Form 10-KT covering the six-month period from January 1, 2026 through June 30, 2026, then begin filing quarterly reports based on the new fiscal year, starting with the quarter ending September 30, 2026.
ANAB submitted a Rule 144 notice reporting 15,467 shares of common stock to be sold in connection with a stock option exercise, with the transaction dated 05/21/2026. The filing also discloses two recent dispositions by Dennis Mulroy of 10,000 shares each on 05/19/2026 and 05/15/2026 for $599,000 and $632,543, respectively.
Dennis Mulroy filed a Form 144 to sell 10,000 shares of Common Stock on 05/19/2026. The excerpt shows the sale is linked to a Stock Option Exercise and lists Morgan Stanley Smith Barney LLC as the brokerage. A prior reported sale of 10,000 shares on 05/15/2026 is shown with proceeds of $632,543.00.
ANAPTYSBIO, INC amendment reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen each beneficially own 55,303 shares of common stock, representing 0.2% of the class. The ownership figures are stated as of the close of business on March 31, 2026.
The filing explains Point72 Asset Management holds investment and voting power over the shares on behalf of an investment fund, Point72 Capital Advisors Inc. is the general partner, and Mr. Cohen controls both entities. The statement clarifies these reporting persons directly own no shares.